Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A form of congenital disorders of N-linked glycosylation characterized by severe neurological involvement, including hypotonia, developmental delay, intellectual disability, postnatal microcephaly, and progressive brain and cerebellar atrophy. Epilepsy with hypsarrythmia is frequently reported. Additional features that may be observed include failure to thrive, arthrogryposis multiplex congenita (AMC), vision impairment (optic atrophy, iris coloboma) and facial dysmorphism (hypertelorism with a broad nasal bridge, large and thick ears, thin lips, micrognathia). The disease is caused by loss of function mutations of the gene ALG3 (3q27.3).
Features include always present findings: Seizure, Type I transferrin isoform profile, Microcephaly, and Spastic tetraparesis and others. 38 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 8 | Flexion contracture, Shrinkage of the cerebellum (cerebellar atrophy), Axial hypotonia |
Brain and nerves | 6 | Seizure, Overactive reflexes (hyperreflexia), Brain shrinkage (cerebral atrophy) |
Arms and legs | 3 | Long fingers, Clinodactyly of the 5th toe, Joint contracture of the hand |
Skin | 2 | Small nail, Nail dysplasia |
Eyes | 2 | Strabismus, Damage to the optic nerve (optic atrophy) |
Head and neck | 2 | High palate, Microcephaly |
Digestive system | 2 | Diarrhea, Vomiting |
Growth and development | 1 | Failure to thrive |
Bones and joints | 1 | Joint contracture of the hand |
ALG3 encodes ALG3 alpha-1,3- mannosyltransferase (438 aa). Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. Highest expression in Cells Cultured fibroblasts (64.9 TPM) and Testis (53.3 TPM).
ALG3-congenital disorder of glycosylation is caused by mutations in the ALG3 gene on chromosome 3.
The ALG3 protein participates in Defective ALG3 causes CDG-1d, Defective ALG3 does not add mannose to the N-glycan precursor, and ALG3 transfers Man to N-glycan precursor (GlcNAc)2 (Man)5 (PP-Dol)1 pathways.
ALG3 is classified as a druggable target (Enzyme category) with score 0.0.
Genetic testing for ALG3 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 6 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for ALG3-congenital disorder of glycosylation.
9 publications have been identified in PubMed for ALG3-congenital disorder of glycosylation. Research spans Basic Science / Preclinical (44%), Case Report / Case Series (33%), and Epidemiology / Natural History (22%).
Sturm D (2026). [PMID: 41967144](https://pubmed.ncbi.nlm.nih.gov/41967144/). *Mol Genet Metab*. [Basic Science / Preclinical]
Alexander JAN (2026). [PMID: 41807832](https://pubmed.ncbi.nlm.nih.gov/41807832/). *Nature chemical biology*. [Basic Science / Preclinical]
Raynor A (2025). [PMID: 41131679](https://pubmed.ncbi.nlm.nih.gov/41131679/). *Journal of inherited metabolic disease*. [Case Report / Case Series]
Lee SJ (2025). [PMID: 39831946](https://pubmed.ncbi.nlm.nih.gov/39831946/). *Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology*. [Case Report / Case Series]
Kodríková R (2025). [PMID: 41089746](https://pubmed.ncbi.nlm.nih.gov/41089746/). *Molecular genetics and metabolism reports*. [Case Report / Case Series]
Navarro-Traxler AJ (2025). [PMID: 40789468](https://pubmed.ncbi.nlm.nih.gov/40789468/). *The Journal of biological chemistry*. [Basic Science / Preclinical]
Zhao P (2025). [PMID: 41437099](https://pubmed.ncbi.nlm.nih.gov/41437099/). *Orphanet journal of rare diseases*. [Epidemiology / Natural History]
Daniel EJP (2024). [PMID: 38597022](https://pubmed.ncbi.nlm.nih.gov/38597022/). *Journal of inherited metabolic disease*. [Basic Science / Preclinical]
Zemet R (2024). [PMID: 38917675](https://pubmed.ncbi.nlm.nih.gov/38917675/). *Molecular genetics and metabolism*. [Epidemiology / Natural History]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 4:38 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about ALG3-congenital disorder of glycosylation
AI-curated news mentioning ALG3-congenital disorder of glycosylation
Updated Jul 21, 2026
FDA approved Casgevy CRISPR gene therapy for children as young as 2 with sickle cell disease on July 1, 2026. Here's what families need to know about this milestone. Approximately 5,500 additional American children are now eligible for this established one-time therapy, according to Vertex Pharmaceuticals, Casgevy's developer. Casgevy also covers transfusion-dependent beta-thalassemia in this new age indication. Sickle cell disease is a lifelong inherited blood disorder that warps red blood cells into stiff, crescent shapes that can block blood flow, starving organs and tissues of oxygen. The world's first CRISPR-based gene therapy has been approved for children as young as two years old, opening the possibility of a single, potentially curative treatment to thousands of American children with sickle cell disease before years of organ damage can narrow what medicine can do for them. Families with children aged 2 and older who have sickle cell disease should speak with their pediatric hematologist about whether Casgevy is appropriate to consider at this stage of their child's disease. Ask specifically which authorized treatment centers perform Casgevy in your region. Treatment is available only at specialized sites, and geographic access remains limited. Contact your child's insurance plan or Medicaid office to ask about coverage. Medicaid coverage for gene therapies varies by state, and some states have developed outcomes-based payment models for high-cost therapies. "With today's decision, pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases," said Karim Mikhail, acting director of the Office of Therapeutic Products at the FDA's Center for Biologics Evaluation and Research, according to the FDA press announcement. Casgevy is a non-viral, ex vivo CRISPR/Cas9 gene-edited cell therapy.